同源康真能打败阿斯利康?

新浪财经
12 Mar

三代EGFR靶向药最近话题不断。3月10日有消息传出,港股上市公司同源康医药的品种TY-9591,在头对头试验中击败阿斯利康的奥希替尼。奥希替尼在中国绝对是标志性药物。从20多年前的吉非替尼开始,阿斯利康几乎垄断了中国肺癌小分子靶向药市场。如今虽然竞品林立,但奥希替尼的高峰始终没人超越。2024年,奥希替尼在中国市场销售保守估计在80亿元以上。▌奥希替尼的神功,就这样被破了?比起 康方生物 来,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10